Niraj Varma News Today

HeartBeam, Inc. (NASDAQ:BEAT) Q3 2023 Earnings Call Transcript November 14, 2023 HeartBeam, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $-0.12. Operator: Greetings and welcome to the HeartBeam Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation. As a reminder, this conference is […]

Operator: Greetings and welcome to the HeartBeam Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov 14, 2023--

Resynchronization therapy jumps forward with 3 new studies that support but push the envelope of a new guideline statement on physiologic pacing for heart failure.

In a major medical breakthrough, Cleveland Clinic has implanted the worlds first dual cardiac device in a patient as part of a clinical trial aimed at treating heart failure symptoms. It was done by top Cleveland experts Bruce Wilkoff and Niraj Varma.

World's First Device Combining CCM Therapy With an ICD in a Single Rechargeable Implant That Treats Both Heart Failure Symptoms and Sudden Cardiac DeathMARLTON, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- Impulse

Cleveland Clinic has successfully implanted a dual cardiac device in the first patient in the world as part of a clinical trial, which aims to potentially treat heart failure symptoms.

The clinical trial, sponsored by Impulse Dynamics, manufacturer of the device, will enroll 300 patients from 75 centers across the U.S. who will be followed for two years.

/PRNewswire/ -- IMPLICITY®, a global leader in remote patient monitoring and cardiac data management solutions, is showcasing its portfolio of remote cardiac...

Clinical and academic researchers can apply for one of three spots for free access to cardiac remote monitoring and ILR ECG Analyzer to support CRM research